[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-349794-105":59,"doc-detail-349794-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","fbxo9-promotes-anti-tumor-immunity-via-degradation-of-pd-l1-in-pancreatic-cancer","FBXO9 promotes anti-tumor immunity via degradation of PD-L1 in pancreatic cancer","","Immune checkpoint blockade targeting PD-1/PD-L1 improves outcomes across many cancers, yet treatment efficacy depends on PD-L1 abundance on tumor cells and associated stromal cells. This study identifies F-box protein 9 (FBXO9) as a novel regulator of PD-L1. FBXO9 upregulation suppresses pancreatic tumor growth and enhances cytotoxic T-cell activation in vivo. Mechanistically, FBXO9 directly binds PD-L1 and promotes its ubiquitination-driven degradation, impairing PD-L1 maturation and tumor immune evasion.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/fbxo9-promotes-anti-tumor-immunity-via-degradation-of-pd-l1-in-pancreatic-cancer/349794/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/fbxo9-promotes-anti-tumor-immunity-via-degradation-of-pd-l1-in-pancreatic-cancer/349794.png","ImageObject",300,407,{"name":92,"@type":93},"Hazel","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What role does FBXO9 play in PD-L1 regulation in pancreatic cancer?","Question",{"text":112,"@type":113},"FBXO9 directly binds PD-L1 and enhances its degradation through ubiquitination, reducing PD-L1 maturation and tumor immune evasion.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does increasing FBXO9 affect tumor behavior and immune activity?",{"text":117,"@type":113},"Higher FBXO9 expression suppresses tumor growth and promotes cytotoxic T-cell activation in vivo.",{"name":119,"@type":110,"acceptedAnswer":120},"How are FBXO9 and PD-L1 levels related in pancreatic cancer tissues?",{"text":121,"@type":113},"FBXO9 expression is decreased in pancreatic cancer tissues versus normal tissues and correlates inversely with PD-L1 levels; lower FBXO9 associates with worse clinical outcome.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},349794,1790169762,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},137441390410,"https://ap-avatar.wpscdn.com/avatar/2000252f4ab5702993?_k=1776741390130283984","TYPE Original Research PUBLISHED 21 January 2026  \nDOI 10.3389/fimmu.2025.1726825  \nOPEN ACCESS  \nEDITED BY  \nXiangpeng Dai,  \nJilin University, China  \nREVIEWED BY  \nZongde Zhang,  \nSouthwest Medical University, China Jia Liu,  \nQingdao University, China Wangpan Shi,  \nUniversity of California, San Diego, United States  \n*CORRESPONDENCE  \nJia Ma  \n [majiamj@bbmc.edu.cn](majiamj@bbmc.edu.cn)[ ](majiamj@bbmc.edu.cn)Hui Xu  \n [xuhui@bbmc.edu.cn](xuhui@bbmc.edu.cn)  \n†These authors have contributed equally to this work  \nRECEIVED 16 October 2025  \nREVISED 16 December 2025  \nACCEPTED 30 December 2025  \nPUBLISHED 21 January 2026  \nCITATION  \nCao T, Zheng R, Wang Y, Yu Z, Huang H, Chen Y, Pan X, Gao Y, Song W, Xia J, Xu Hand Ma J (2026) FBXO9 promotes anti-tumor immunity via degradation of PD-L1 in pancreatic cancer.  \nFront. Immunol. 16:1726825 .  \ndoi: 10.3389/fimmu.2025.1726825  \nCOPYRIGHT  \n© 2026 Cao, Zheng, Wang, Yu, Huang, Chen, Pan, Gao, Song, Xia, Xu and Ma. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nFBXO9 promotes anti-tumor immunity via degradation of PD-L1 in pancreatic cancer  \nTong Cao 1†, Rui Zheng 2†, Yingying Wang 2†, Zixuan Yu 3, Hua Huang 4, Yufo Chen 5, Xueshan Pan 2, Yu Gao 6, Wenqing Song 7, Jun Xia 3, Hui Xu 2* and Jia Ma 2,3*  \n1 Department of Clinical Laboratory, the First Afﬁliated Hospital of Bengbu Medical University, Bengbu, Anhui, China, 2 Bengbu Medical University Key Laboratory of Cancer Research and Clinical Laboratory Diagnosis, Bengbu Medical University, Bengbu, Anhui, China, 3School of Clinical Medicine, Bengbu Medical University, Bengbu, Anhui, China, 4School of Laboratory Medicine, Bengbu Medical University, Bengbu, Anhui, China, 5 Department of Medical Oncology, The First Afﬁliated Hospital of Bengbu Medical University, Bengbu, Anhui, China, 6School of Life Science, Bengbu Medical University, Laboratory Animal Center, Bengbu, Anhui, China, 7 Department of Pathology, Bengbu Medical University, Bengbu, Anhui, China  \nImmune checkpoint blockade therapy, particularly those targeting programmed death 1/programmed cell death ligand 1 (PD-1/PD-L1), has been extensively employed to treat various human cancers, signiﬁcantly improving clinical outcomes. Increasing evidence reveals that the therapeutic efﬁcacy of PD-1/ PD-L1 inhibitors depends on the abundance of PD-L1 on cancer cells and tumorassociated stromal cells. Here, we demonstrated that F-box protein 9 (FBXO9) is a novel regulator of PD-L1 . We found that increased expression of FBXO9 suppresses tumor growth and promotes cytotoxic T cell activation in vivo. Mechanistically, FBXO9 directly binds to PD-L1 protein and enhances its degradation via ubiquitination, thereby impeding PD-L1 maturation and tumor immune evasion. Meanwhile, the expression of FBXO9 is decreased in pancreatic cancer tissues in comparison to normal tissues. Furthermore, FBXO9 expression correlates inversely with PD-L1 levels, with lower FBXO9 expression being associated with worse clinical outcome. These ﬁndings identify FBXO9 as a tumor suppressor via its facilitation of PD-L1 degradation, underscoring the potential of targeting FBXO9 in immunotherapeutic approaches for treating cancers, particularly in combination with anti-PD-L1 therapy.  \nKEYWORDS  \ndegradation, FBXO9, immunotherapy, pancreatic cancer, PD-1, PD-L1  \nIntroduction  \nPancreatic cancer is highly lethal malignancy, ranking as the 7th leading cause of cancer-related deaths worldwide. Despite advancement in diagnostics, chemotherapy, radiotherapy and combination therapies, most patients with pancreatic cancer con","cbCaibJH7GbJ1Pmn","https://ap.wps.com/l/cbCaibJH7GbJ1Pmn","pdf",2726965,13,"English","# Introduction\n## PD-1/PD-L1 checkpoint blockade and clinical need in pancreatic cancer\n## PD-L1 biology and immune evasion mechanisms\n## Rationale for targeting PD-L1 regulation and PTMs\n# Key findings and mechanistic focus","[{\"question\":\"What role does FBXO9 play in PD-L1 regulation in pancreatic cancer?\",\"answer\":\"FBXO9 directly binds PD-L1 and enhances its degradation through ubiquitination, reducing PD-L1 maturation and tumor immune evasion.\"},{\"question\":\"How does increasing FBXO9 affect tumor behavior and immune activity?\",\"answer\":\"Higher FBXO9 expression suppresses tumor growth and promotes cytotoxic T-cell activation in vivo.\"},{\"question\":\"How are FBXO9 and PD-L1 levels related in pancreatic cancer tissues?\",\"answer\":\"FBXO9 expression is decreased in pancreatic cancer tissues versus normal tissues and correlates inversely with PD-L1 levels; lower FBXO9 associates with worse clinical outcome.\"}]","FBXO9 promotes anti-tumor immunity via degradation of PD-L1 in pancreatic cancer | PDF",1790085601,33,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1766b1426ad4337345f495c6678cdd6e.webp",983,1389,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3dcee3631d193857bd5852913060ea9d.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4df9840fbc88162b5680df76f4971872.webp",981,1386,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b8bf22997776cbb80ffd9f4f5d11d5db.webp",980,1385]